Clinical Trial Update: Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating oral sildenafil citrate to improve maternal and neonatal outcomes in low-resource settings has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrapartum Fetal Distress
• Neonatal Asphyxia

Drugs mentioned

• Sildenafil citrate (Sildenafil citrate)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Intrapartum Fetal Distress, Neonatal Asphyxia | Phase 3 | Status: WITHDRAWN